Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial

Ying–Hong Shi, Guohong Han, Jian Zhou, Xuetao Shi, Weidong Jia, Ying Cheng, Yongdong Jin, Xiangdong Hua, Tianfu Wen, Jianbing Wu, Shanzhi Gu, Yuxian Bai, Xiangcai Wang, Tao Zhang, Zhiyu Chen, Bixiang Zhang, Ming Huang, Hongming Liu, Yilei Mao, Ledu Zhou, Rui Wang, Yunfeng Shan, Wu Zhang, Tianqiang Song, Yabing Guo, Fuxiang Zhou, Bingfeng Shao, Mingjun Zhang, Bo Liang, Jinfang Zheng, Guoping Zhang, Jie Shen, Weiwen Su, Feng Zhang, Yifu He, Sheng Hu, Rong Liu, Cheng-Wu Zhang, Shunli Shen, Hui Zeng, Tsang-En Wang, Wenzhi Guo, Yan Shen, Yajin Chen, Y. Li, Jens Samol, Hong-Tao Hu, Wenhua Zhang, Chengyou Du, Enxiao Li, Chao Liu, Choo Su Pin, Xun Li, Hao Xu, Jee‐Fu Huang, Chunyi Hao, Jing Lv, Wei Wang, Qian Xu, Aobing Bai, Xiao Zhang, Bi‐Feng Liu, Chunlei Jin, Jia Fan